This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (290)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Phase Z of the A to Z Trial

James A. de Lemos, MD; Michael A. Blazing, MD; Stephen D. Wiviott, MD; Eldrin F. Lewis, MD; Keith A. A. Fox, MB, ChB; Harvey D. White, DSc; Jean-Lucien Rouleau, MD; Terje R. Pedersen, MD; Laura H. Gardner, BSPH; Robin Mukherjee, PhD; Karen E. Ramsey, BS, RPh; Joanne Palmisano, MD; David W. Bilheimer, MD; Marc A. Pfeffer, MD, PhD; Robert M. Califf, MD; Eugene Braunwald, MD; for the A to Z Investigators

JAMA. 2004;292:1307-1316. Published online August 30, 2004 (doi:10.1001/jama.292.11.1307).

Context  Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome.

Objective  To compare early initiation of an intensive statin regimen with delayed initiation of a less intensive regimen in patients with ACS.

Design, Setting, and Participants  International, randomized, double-blind trial of patients with ACS receiving 40 mg/d of simvastatin for 1 month followed by 80 mg/d thereafter (n = 2265) compared with ACS patients receiving placebo for 4 months followed by 20 mg/d of simvastatin (n = 2232), who were enrolled in phase Z of the A to Z trial between December 29, 1999, and January 6, 2003.

Main Outcome Measure  The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, readmission for ACS, and stroke. Follow-up was for at least 6 months and up to 24 months.

Results  Among the patients in the placebo plus simvastatin group, the median low-density lipoprotein (LDL) cholesterol level achieved while taking placebo was 122 mg/dL (3.16 mmol/L) at 1 month and was 77 mg/dL (1.99 mmol/L) at 8 months while taking 20 mg/d of simvastatin. Among the patients in the simvastatin only group, the median LDL cholesterol level achieved at 1 month while taking 40 mg/d of simvastatin was 68 mg/dL (1.76 mmol/L) and was 63 mg/dL (1.63 mmol/L) at 8 months while taking 80 mg/d of simvastatin. A total of 343 patients (16.7%) in the placebo plus simvastatin group experienced the primary end point compared with 309 (14.4%) in the simvastatin only group (40 mg/80 mg) (hazard ratio [HR], 0.89; 95% confidence interval [CI] 0.76-1.04; P = .14). Cardiovascular death occurred in 109 (5.4%) and 83 (4.1%) patients in the 2 groups (HR, 0.75; 95% CI, 0.57-1.00; P = .05) but no differences were observed in other individual components of the primary end point. No difference was evident during the first 4 months between the groups for the primary end point (HR, 1.01; 95% CI, 0.83-1.25; P = .89), but from 4 months through the end of the study the primary end point was significantly reduced in the simvastatin only group (HR, 0.75; 95% CI, 0.60-0.95; P = .02). Myopathy (creatine kinase >10 times the upper limit of normal associated with muscle symptoms) occurred in 9 patients (0.4%) receiving simvastatin 80 mg/d, in no patients receiving lower doses of simvastatin, and in 1 patient receiving placebo (P = .02).

Conclusions  The trial did not achieve the prespecified end point. However, among patients with ACS, the early initiation of an aggressive simvastatin regimen resulted in a favorable trend toward reduction of major cardiovascular events.

Author Affiliations: Donald W. Reynolds Cardiovascular Clinical Research Center, the University of Texas Southwestern Medical Center, Dallas (Dr de Lemos); Duke Clinical Research Institute, Durham, NC (Drs Blazing and Califf and Ms Gardner); Department of Medicine, Brigham and Women's Hospital, Boston, Mass (Drs Wiviott, Lewis, Pfeffer, and Braunwald); Department of Cardiology Research, University of Edinburgh, Edinburgh, Scotland (Dr Fox); Department of Cardiology, Green Lane Hospital, Auckland, New Zealand (Dr White); Department of Medicine, University of Montreal, Montreal, Quebec (Dr Rouleau); Centre for Preventive Medicine, Ullevål University Hospital, Oslo, Norway (Dr Pedersen); and Merck & Company, Whitehouse Station, NJ (Drs Mukherjee, Palmisano, and Bilheimer and Ms Ramsey).

RELATED LETTERS

High-Dose Statins in Acute Coronary Syndromes
John R. Crouse, III
JAMA. 2005;293(1):36.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Bruce Ovbiagele
JAMA. 2005;293(1):36-37.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Yale B. Mitchel
JAMA. 2005;293(1):37.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
William L. Isley
JAMA. 2005;293(1):37-38.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Michael H. Davidson
JAMA. 2005;293(1):38.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes—Reply
James A. de Lemos, Michael A. Blazing, Robert M. Califf, Stephen D. Wiviott, and Eugene Braunwald
JAMA. 2005;293(1):38-39.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes—Reply
Steven E. Nissen
JAMA. 2005;293(1):39.
EXTRACT | FULL TEXT  

RELATED ARTICLE

High-Dose Statins in Acute Coronary Syndromes: Not Just Lipid Levels
Steven E. Nissen
JAMA. 2004;292(11):1365-1367.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?
Talelli and Greenwood
Therapeutic Advances in Cardiovascular Disease 2008;2:387-405.
ABSTRACT  

NICE lipid modification guideline: both absolute and obsolete!
Olsson
Heart 2008;94:1256-1257.
FULL TEXT  

Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis
Giraldez et al.
J Am Coll Cardiol 2008;52:914-920.
ABSTRACT | FULL TEXT  

Which Statin?
Obstet Gynecol 2008;112:696-698.
FULL TEXT  

SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study
The SEARCH Collaborative Group
NEJM 2008;359:789-799.
ABSTRACT | FULL TEXT  

The Effects of Medications on Myocardial Perfusion
Zoghbi et al.
J Am Coll Cardiol 2008;52:401-416.
ABSTRACT | FULL TEXT  

Statins and Heart Failure
Filippatos and Mikhailidis
ANGIOLOGY 2008;59:58S-61S.
ABSTRACT  

CORONA, Statins, and Heart Failure: Who Lost the Crown?
Athyros et al.
ANGIOLOGY 2008;59:5-8.
 

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan et al.
CMAJ 2008;178:576-584.
ABSTRACT | FULL TEXT  

LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?
Nesto
Clin. Diabetes 2008;26:8-13.
ABSTRACT | FULL TEXT  

Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study
Kinlay et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:142-147.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes: Results From the A to Z Trial
de Lemos et al.
J Am Coll Cardiol 2007;50:2117-2124.
ABSTRACT | FULL TEXT  

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Authors/Task Force Members et al.
Eur Heart J 2007;28:2375-2414.
FULL TEXT  

Diabetes and Mortality Following Acute Coronary Syndromes
Donahoe et al.
JAMA 2007;298:765-775.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
Leeper et al.
Circulation 2007;116:613-618.
ABSTRACT | FULL TEXT  

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo et al.
Heart 2007;93:914-921.
ABSTRACT | FULL TEXT  

Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice
Choudhry et al.
Heart 2007;93:945-951.
ABSTRACT | FULL TEXT  

Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
Alsheikh-Ali et al.
J Am Coll Cardiol 2007;50:409-418.
ABSTRACT | FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2570-2589.
ABSTRACT | FULL TEXT  

Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease
Chan et al.
Circulation 2007;115:2398-2409.
ABSTRACT | FULL TEXT  

Update on Dyslipidemia
Garg and Simha
J. Clin. Endocrinol. Metab. 2007;92:1581-1589.
ABSTRACT | FULL TEXT  

Safety of Aggressive Lipid Management
Davidson and Robinson
J Am Coll Cardiol 2007;49:1753-1762.
ABSTRACT | FULL TEXT  

Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial
Morrow et al.
JAMA 2007;297:1775-1783.
ABSTRACT | FULL TEXT  

Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Song et al.
Am J Health Syst Pharm 2007;64:767-772.
ABSTRACT | FULL TEXT  

Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention: Results of the ARMYDA-ACS Randomized Trial
Patti et al.
J Am Coll Cardiol 2007;49:1272-1278.
ABSTRACT | FULL TEXT  

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel et al.
Eur Heart J 2007;28:664-672.
ABSTRACT | FULL TEXT  

Lipid-Lowering Therapy and Outcomes in Heart Failure
Ray et al.
J CARDIOVASC PHARMACOL THER 2007;12:27-35.
ABSTRACT  

Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization
Klein
J Am Coll Cardiol 2007;49:271-273.
FULL TEXT  

Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Dzau et al.
Circulation 2006;114:2871-2891.
FULL TEXT  

Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies
Kapoor et al.
BMJ 2006;333:1149-1149.
ABSTRACT | FULL TEXT  

Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
Milani and Lavie
J Am Coll Cardiol 2006;48:1791-1792.
FULL TEXT  

Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives: [Le role des statines dans la reduction du risque cardiaque perioperatoire : perspectives physiologiques et cliniques].
Boushra and Muntazar
Canadian J. Anesthesia 2006;53:1126-1147.
ABSTRACT | FULL TEXT  

Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed et al.
Eur Heart J 2006;27:2323-2329.
ABSTRACT | FULL TEXT  

The gap between theory and practice: what do the trials tell us?
Pedersen
Eur Heart J Suppl 2006;8:F10-F16.
ABSTRACT | FULL TEXT  

Reducing risk by raising HDL-cholesterol: the evidence
Drexel
Eur Heart J Suppl 2006;8:F23-F29.
ABSTRACT | FULL TEXT  

Niaspan(R) in the management of dyslipidaemia: the evidence
Brown
Eur Heart J Suppl 2006;8:F60-F67.
ABSTRACT | FULL TEXT  

Evidence to support aggressive management of HDL-cholesterol: implications of recent trials
Taylor
Eur Heart J Suppl 2006;8:F74-F80.
ABSTRACT | FULL TEXT  

The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
Hulten et al.
Arch Intern Med 2006;166:1814-1821.
ABSTRACT | FULL TEXT  

CRP promotes monocyte-endothelial cell adhesion via Fc{gamma} receptors in human aortic endothelial cells under static and shear flow conditions
Devaraj et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1170-H1176.
ABSTRACT | FULL TEXT  

Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy
Cannon et al.
J Am Coll Cardiol 2006;48:438-445.
ABSTRACT | FULL TEXT  

Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes
Lenderink et al.
Eur Heart J 2006;27:1799-1804.
ABSTRACT | FULL TEXT  

Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Morrow et al.
Circulation 2006;114:281-288.
ABSTRACT | FULL TEXT  

Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended-Release Niacin
LaFleur et al.
The Annals of Pharmacotherapy 2006;40:1274-1279.
ABSTRACT | FULL TEXT  

High-dose statins and the IDEAL study.
Chan et al.
JAMA 2006;295:2477-2477.
FULL TEXT  

High-dose statins and the IDEAL study.
Ong and Cheah
JAMA 2006;295:2476-2477.
FULL TEXT  

Statins, diet, and low cholesterol.
Arora and Balamuthusamy
JAMA 2006;295:2479-2479.
FULL TEXT  

Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study
Scirica et al.
J Am Coll Cardiol 2006;47:2326-2331.
ABSTRACT | FULL TEXT  

Statin-Induced Myopathy: The Two Faces of Janus
Arora et al.
J CARDIOVASC PHARMACOL THER 2006;11:105-112.
ABSTRACT  

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
Smith et al.
J Am Coll Cardiol 2006;47:2130-2139.
FULL TEXT  

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
Smith et al.
Circulation 2006;113:2363-2372.
FULL TEXT  

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel et al.
JAMA 2006;295:2046-2056.
ABSTRACT | FULL TEXT  

The Verdict Is Still Out
Scirica et al.
Circulation 2006;113:2128-2151.
FULL TEXT  

C-Reactive Protein and the Vascular Endothelium: Implications for Plaque Instability
Jialal et al.
J Am Coll Cardiol 2006;47:1379-1381.
FULL TEXT  

Introduction: Pharmacotherapy for Dyslipidemia
Dumo
Journal of Pharmacy Practice 2006;19:61-62.
 

Direct Comparison of the A to Z and PROVE IT Trials: A Second Chance to Gain a First Impression
Brown
Circulation 2006;113:1382-1384.
FULL TEXT  

A Tale of Two Trials: A Comparison of the Post-Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT-TIMI 22
Wiviott et al.
Circulation 2006;113:1406-1414.
ABSTRACT | FULL TEXT  

Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction
Iwakura et al.
Eur Heart J 2006;27:534-539.
ABSTRACT | FULL TEXT  

Coronary Artery Calcium: Should We Rely on This Surrogate Marker?
Redberg
Circulation 2006;113:336-337.
FULL TEXT  

Balancing Statin Therapy Guidelines With Practice
Hendry
DOC News 2006;3:10-11.
FULL TEXT  

Standards of Medical Care in Diabetes-2006
American Diabetes Association
Diabetes Care 2006;29:S4-S42.
FULL TEXT  

Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery Disease
Morrow et al.
JAMA 2005;294:2866-2871.
ABSTRACT | FULL TEXT  

Mechanisms of Statin-Induced Myopathy: A Role for the Ubiquitin-Proteasome Pathway?
Chapman and Carrie
Arterioscler. Thromb. Vasc. Bio. 2005;25:2441-2444.
FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Part 5: Acute Coronary Syndromes
Circulation 2005;112:III-55-III-72.
FULL TEXT  

The IDEAL Cholesterol: Lower Is Better
Cannon
JAMA 2005;294:2492-2494.
FULL TEXT  

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT | FULL TEXT  

In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes: Maximizing the Early and Long-term Benefits
Fonarow
Chest 2005;128:3641-3651.
ABSTRACT | FULL TEXT  

Perspectives on Dyslipidemia and Coronary Heart Disease in Women
Bittner
J Am Coll Cardiol 2005;46:1628-1635.
ABSTRACT | FULL TEXT  

Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy: A PROVE IT-TIMI 22 Substudy
Wiviott et al.
J Am Coll Cardiol 2005;46:1411-1416.
ABSTRACT | FULL TEXT  

C-Reactive Protein Increase in Unstable Coronary Disease: Cause or Effect?
De Servi et al.
J Am Coll Cardiol 2005;46:1496-1502.
ABSTRACT | FULL TEXT  

Relation of Characteristics of Metabolic Syndrome to Short-Term Prognosis and Effects of Intensive Statin Therapy After Acute Coronary Syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
Schwartz et al.
Diabetes Care 2005;28:2508-2513.
ABSTRACT | FULL TEXT  

Lipid Management with Statins in Type 2 Diabetes Mellitus
Irons and Kroon
The Annals of Pharmacotherapy 2005;39:1714-1718.
ABSTRACT | FULL TEXT